A Phase 1/2 interventional study of Glycopyrrolate and Anisodamine in Nausea and Vomiting, sponsored by Jie Chen. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-05.
Sponsored by Jie Chen · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Nausea with a site in China — 20 open to participants now, 20 under way, 9 of them phase 3. Nausea · China.
Among the 42 studies in Nausea with a site in China, this one is the 19th largest by enrollment of the 39 interventional ones that give a count, is one of 3 that started in 2023, is the only one in phase 1/2, and was the 25th registered.
646 studies on the registry are indexed under Nausea; 87 are open to participants now.
Browse Nausea studies →20 of the 42 studies in Nausea with a site in China are open now. Recruiting first, the newest first:
Sun Yat-sen University · Sites in China
Ages 18+
Affiliated Hospital of Qinghai University · Sites in China
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–85
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–85
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–85
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 53 Nausea studies recruiting now, 23 (43%) set no upper age limit and 19 (36%) stop at 75 or younger; 10 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 12 · Phase 3 15 · Phase 4 2
First in 2006; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 130 is above the median of 96 across 546 interventional studies indexed under Nausea.
Median enrollment 122 across the 39 interventional studies, 2,493 across the 3 observational. Of the 16 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 42 have an industry lead sponsor. The 10 most frequent:
Jie Chen is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
Jie Chen has 1 study filed under Nausea — fewer than ten, so there is no comparison to draw.
9 of the studies in Nausea with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07716228Phase 3Second Affiliated Hospital, School of Medicine, Zhejiang UniversityAuricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Gemcitabine Combined With Paclitaxel Protein-bound | 2026-12-06 |
| NCT07716189Phase 3Second Affiliated Hospital, School of Medicine, Zhejiang UniversityAuricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Trastuzumab Deruxtecan | 2026-12-06 |
| NCT07716176Phase 3Second Affiliated Hospital, School of Medicine, Zhejiang UniversityAuricular Point Stimulation Plus Dexamethasone Versus Standard Antiemetic Regimen for Nausea and Vomiting Caused by Docetaxel Plus Cyclophosphamide | 2026-12-06 |
| NCT06314906Phase 3Feixue SongElectroacupuncture Plus Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer | 2027-01-31 |
| NCT07537699Second Affiliated Hospital, School of Medicine, Zhejiang UniversityAuricular Point Stimulation Plus Dexamethasone for Nausea and Vomiting Caused by Docetaxel Plus Cyclophosphamide | 2026-11 |
Add all 9 to your calendar (.ics) → With an account.
Among the 42 studies in Nausea with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to determine the role of Glycopyrrolate in preventing postoperative nausea and vomiting of ERCP.
This study is a prospective, double-blind, randomized controlled trial. Patients who meet the criteria of our center and need to undergo ERCP lesion resection will be included and randomly divided into groups. After receiving Glycopyrrolate (experimental group) and Anisodamine (control group), duodenal peristalsis, biliary and pancreatic treatment time and postoperative nausea and vomiting will be observed during therapeutic ERCP. The inhibitory effect of Glycopyrrolate on postoperative nausea and vomiting of ERCP will be analyzed statistically.
Main outcome measure: incidence of nausea and vomiting after ERCP Secondary outcome measures: mean duodenal contractions per minute, duodenal spasm frequency and score, ERCP operation time, occurrence of other side effects of medication, remedial medication, and incidence of adverse events
Inclusion Criteria:
Exclusion Criteria:1: Use of anticholinergic drugs
2: pregnancy
3: glaucoma
4: Myasthenia gravis
5: Obstructive gastrointestinal diseases
6: Obstructive urinary tract disease (prostatic hyperplasia)
7: Heart disease (coronary heart disease, congestive heart failure)
8: hyperthyroidism
9: Previous history of abdominal or intestinal surgery
10: Chronic renal failure
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
During induction of anesthesia, 0.2mg Glycopyrrolate was given intravenously to participants.
Drug: Glycopyrrolate
During induction of anesthesia,10mg of Anisodamine was given intramuscular injection
Drug: Anisodamine
During induction of anesthesia, 0.2mg Glycopyrrolate was given intravenously
During induction of anesthesia,10mg of Anisodamine was given intramuscular injection.
Incidence of postoperative nausea and vomiting
Time frame: Timepoint:24 hours after the ERCP
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2023 to primary completion in Jul 2024, 9 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Glycopyrrolate
Jie Chen